scholarly journals Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice

2017 ◽  
Vol 2 (1) ◽  
pp. 69-83 ◽  
Author(s):  
Esther Nuñez‐Durán ◽  
Mariam Aghajan ◽  
Manoj Amrutkar ◽  
Silva Sütt ◽  
Emmelie Cansby ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Liver Disease ◽  
Protein Kinase ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Glucose Intolerance ◽  
Antisense Oligonucleotide ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver

Considering the Links Between Nonalcoholic Fatty Liver Disease and Insulin Resistance: Revisiting the Role of Protein Kinase C ε

Hepatology ◽  
2019 ◽  
Vol 70 (6) ◽  
pp. 2217-2220 ◽  
Author(s):  
Varman T. Samuel ◽  
Max C. Petersen ◽  
Brandon M. Gassaway ◽  
Daniel F. Vatner ◽  
Jesse Rinehart ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Protein Kinase C ◽  
Liver Disease ◽  
Protein Kinase ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver ◽  
Kinase C

scholarly journals Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease

2007 ◽  
Vol 117 (3) ◽  
pp. 739-745 ◽  
Author(s):  
Varman T. Samuel ◽  
Zhen-Xiang Liu ◽  
Amy Wang ◽  
Sara A. Beddow ◽  
John G. Geisler ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Liver Disease ◽  
Protein Kinase ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Hepatic Insulin Resistance ◽  
Nonalcoholic Fatty Liver

scholarly journals Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease and Urinary Chromium Loss in Obese Mice

2021 ◽  
Vol 14 (3) ◽  
pp. 267
Author(s):  
Geng-Ruei Chang ◽  
Po-Hsun Hou ◽  
Wei-Cheng Yang ◽  
Chao-Min Wang ◽  
Pei-Shan Fan ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Glucose Intolerance ◽  
Fatty Liver Disease ◽  
Renal Damage ◽  
Liver Lipid ◽  
Interleukin 1 ◽  
Mrna Levels ◽  
Nonalcoholic Fatty Liver

Doxepin is commonly prescribed for depression and anxiety treatment. Doxepin-related disruptions to metabolism and renal/hepatic adverse effects remain unclear; thus, the underlying mechanism of action warrants further research. Here, we investigated how doxepin affects lipid change, glucose homeostasis, chromium (Cr) distribution, renal impairment, liver damage, and fatty liver scores in C57BL6/J mice subjected to a high-fat diet and 5 mg/kg/day doxepin treatment for eight weeks. We noted that the treated mice had higher body, kidney, liver, retroperitoneal, and epididymal white adipose tissue weights; serum and liver triglyceride, alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, and creatinine levels; daily food efficiency; and liver lipid regulation marker expression. They also demonstrated exacerbated insulin resistance and glucose intolerance with lower Akt phosphorylation, GLUT4 expression, and renal damage as well as higher reactive oxygen species and interleukin 1 and lower catalase, superoxide dismutase, and glutathione peroxidase levels. The treated mice had a net-negative Cr balance due to increased urinary excretion, leading to Cr mobilization, delaying hyperglycemia recovery. Furthermore, they had considerably increased fatty liver scores, paralleling increases in adiponectin, FASN, PNPLA3, FABP4 mRNA, and SREBP1 mRNA levels. In conclusion, doxepin administration potentially worsens renal injury, nonalcoholic fatty liver disease, and diabetes.

scholarly journals A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver Disease

2018 ◽  
Vol 2 (12) ◽  
pp. 1467-1478 ◽  
Author(s):  
Christopher J. Danford ◽  
Margery A. Connelly ◽  
Irina Shalaurova ◽  
Misung Kim ◽  
Mark A. Herman ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver
Sign in / Sign up

Export Citation Format

Share Document